Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Clinical trial NCT05311618 · UNKNOWN

Trial details

NCT number: NCT05311618
Sponsor: NGM Biopharmaceuticals, Inc
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Pancreatic Cancer Breast Cancer Gastric Cancer Non Small Cell Lung Cancer Cervical Cancer Endocervical Cancer Squamous Cell Carcinoma of Head and Neck Bladder Urothelial Cancer Colorectal Cancer Esophageal Cancer Ovarian Cancer Renal Cell Carcinoma

Start date: 2022-05-11
Primary completion: 2025-04-01
Enrollment: 71

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.